-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HNliaE3ZM+eUKphEosfZKWYjtWnZZH/wqfPx/uTtnPJ2QRMur44LvWK67NOWV45N tA4rQLgT/i7trb865tSeVw== 0000950116-04-000355.txt : 20040203 0000950116-04-000355.hdr.sgml : 20040203 20040203133150 ACCESSION NUMBER: 0000950116-04-000355 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030129 ITEM INFORMATION: Other events FILED AS OF DATE: 20040203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25169 FILM NUMBER: 04562025 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANADA STATE: A1 ZIP: M5J 2G2 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CA STATE: A1 ZIP: M5J 2G2 8-K 1 eight-k.htm 8-K Prepared and filed by St Ives Burrups

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 8-K

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) January 29, 2003
 


Generex Biotechnology Corporation

(Exact name of registrant as specified in its charter)


Delaware   000-25169   98-0178636



(State or other jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)


33 Harbor Square, Suite 202, Toronto, Ontario Canada   M5J 2G2

 
(Address of principal executive offices)   (Zip Code)


Registrant's telephone number, including area code     416/364-2551
   



(Former name or former address, if changed since last report)


Item 5.      Other Events.

On January 29, 2003 Peter Levitch and Pankaj Modi, Ph.D. each resigned as a member of the Board of Directors. Mr. Levitch will serve the Company as a consultant in regulatory matters. Dr. Modi will remain as Vice President, Research and Development of the Company in accordance with the terms of his consulting agreement, dated October 1, 1996, as amended.


SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


      GENEREX BIOTECHNOLOGY CORPORATION
       
       
       
       
       
Dated: February 3, 2003 By: /s/ Rose Perri
 
 
      Rose Perri
      Chief Operating Officer


-----END PRIVACY-ENHANCED MESSAGE-----